Table 5.
Hydrophobically modified glycol chitosan.
| Hydrophobic moiety | Active agent | Particle size (nm) | Zeta-potential (mV) | Ref. |
|---|---|---|---|---|
| Cholanic acid | Docetaxel | 350 b | +23.8 ± 0.9 a +10.0 ± 0.8 b |
[165] |
| Camptothecin | 254 a | [166] | ||
| 279–328 b | ||||
| siRNA | 350 a | [167] | ||
| 250 b | ||||
| RGD peptide | 224 a | [168] | ||
| 189–265 b | ||||
| Cholesterol | Indomethacin | 228 a | [169] | |
| 275–384 b | ||||
| Deoxycholic acid | Palmityl-acylated exendin-4 | ~52–250 a | [170] | |
| Ergocalciferol | Vitamin D2 | 279 ± 7 (PBS) | +7.7 ± 0.1 | [171] |
| dl-α-tocopherol | Vitamin E | 284–496 (PBS) | +11.7 to +36.5 | [172] |
| Testosterone | Testosterone | 332 ± 4 (PBS) | +9.7 ± 0.6 | [173] |
| N,N-diethylnicotinamide-based oligomer | Paclitaxel | 313 ± 20 a | [174] | |
| 331–363 b | ||||
| 3-Diethylaminopropyl | Doxorubicin | 102 a | −0.9 a | [175] |
| Doxorubicin | Doxorubicin | 238 a 342 b |
[176] |
a Unloaded particle; b loaded particle.